Search
Dianthus Therapeutics Inc
DNTHAdd to Watchlist
106.920USD
-5.720-5.08%
Close 07-31 16:00（ET）Quotes delayed by 15 min
5.84BMarket Cap
LossP/E TTM
More Details of Dianthus Therapeutics Inc Company
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
Dianthus Therapeutics Inc Info
Ticker SymbolDNTH
Company nameDianthus Therapeutics Inc
IPO dateJun 21, 2018
CEOGarcia (Marino)
Number of employees78
Security typeOrdinary Share
Fiscal year-endJun 21
Address7 Times Square
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10036
Phone19299994055
Websitehttps://dianthustx.com/
Ticker SymbolDNTH
IPO dateJun 21, 2018
CEOGarcia (Marino)
Company Executives of Dianthus Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Marino Garcia
Mr. Marino Garcia
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.29K
--
Dr. Simrat Randhawa, M.D.
Dr. Simrat Randhawa, M.D.
Chief Medical Officer
Chief Medical Officer
4.00K
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Anne McGeorge
Ms. Anne McGeorge
Independent Director
Independent Director
--
--
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
--
--
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ryan Savitz
Mr. Ryan Savitz
Chief Financial Officer, Chief Business Officer Treasurer
Chief Financial Officer, Chief Business Officer Treasurer
--
--
Mr. Edward Carr
Mr. Edward Carr
Chief Accounting Officer
Chief Accounting Officer
--
--
Mr. Adam M. Veness, Esq., J.D.
Mr. Adam M. Veness, Esq., J.D.
Senior Vice President, General Counsel, Company Secretary
Senior Vice President, General Counsel, Company Secretary
--
--
Mr. Steven Romano
Mr. Steven Romano
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Marino Garcia
Mr. Marino Garcia
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.29K
--
Dr. Simrat Randhawa, M.D.
Dr. Simrat Randhawa, M.D.
Chief Medical Officer
Chief Medical Officer
4.00K
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Anne McGeorge
Ms. Anne McGeorge
Independent Director
Independent Director
--
--
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
--
--
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Dianthus Therapeutics Inc?
The top five shareholders of Dianthus Therapeutics Inc are: Mr. Marino Garcia
How many institutions hold shares of Dianthus Therapeutics Inc (DNTH)?
As of 2026Q1, 342 institutions hold shares of Dianthus Therapeutics Inc, with a combined market value of approximately 54.50M, accounting for 99.70% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 5319432.00.